Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.63 |
| ▸ | FPR2 | P25090 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16116802 | 1.00 | LDHA (0.63) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL30062882 | 0.88 | LDHA (0.59) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL1097490 | 0.88 | LDHA (0.63) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL28382375 | 0.86 | LDHA (0.61) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL12302732 | 0.86 | LDHA (0.53) | LDHAFPR2KMT2A | |
| SCHEMBL6307236 | 0.84 | LDHA (0.55) | LDHAFPR2KMT2ACA2MMP2 | |
| SCHEMBL995624 | 0.84 | LDHA (0.67) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL2029603 | 0.84 | LDHA (0.67) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL7751730 | 0.84 | LDHA (0.67) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL16063575 | 0.84 | LDHA (0.67) | LDHAFPR2KMT2ACA2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079491-B1 | N-SUBSTITUTED MONOMERS AND POLYMERS | REVA MEDICAL INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8288590-B2 | N-substituted monomers and polymers | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-10-16 | — | — | US | disclosed |
| US-8143052-B2 | Process for preparing optically active (S or R)-α amino acid and (R or S)-α amino acid ester in one phase organic reaction medium | UBE INDUSTRIES, LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20110269848-A1 | N-SUBSTITUTED MONOMERS AND POLYMERS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-11-03 | — | — | US | disclosed |
| US-8034365-B2 | Polymer substituted with amide or thioamide groups; vascular stents, bioreabsorbable polymers | REVA MEDICAL, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034365-B2 | Polymer substituted with amide or thioamide groups; vascular stents, bioreabsorbable polymers | REVA MEDICAL, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-8008528-B2 | Polymers substituted with amide or thioamide groups; vascular stents; bioreabsorable polymer; low viscosity melt | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-08-30 | — | — | US | disclosed |
| WO-2008100346-A2 | N-SUBSTITUTED MONOMERS AND POLYMERS | REVA MEDICAL, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080187567-A1 | N-SUBSTITUTED MONOMERS AND POLYMERS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-08-07 | — | — | US | disclosed |
| US-20080187567-A1 | N-SUBSTITUTED MONOMERS AND POLYMERS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-08-07 | — | — | US | disclosed |
| WO-2008082738-A2 | N-SUBSTITUTED MONOMERS AND POLYMERS | RUTGERS, THE STATE UNIVERSITY (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080112999-A1 | N-SUBSTITUTED MONOMERS AND POLYMERS | REVA MEDICAL, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080112999-A1 | N-SUBSTITUTED MONOMERS AND POLYMERS | REVA MEDICAL, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269848-A1 | N-SUBSTITUTED MONOMERS AND POLYMERS | NANS, NCL, PNISR | LDHA 1971/4885FPR2 1194/4885KMT2A 3118/4885 |
| US-20080187567-A1 | N-SUBSTITUTED MONOMERS AND POLYMERS | NANS, NCL, PNISR | LDHA 1971/4885FPR2 1194/4885KMT2A 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.